These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20188202)

  • 21. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.
    Björklund AT; Schaffer M; Fauriat C; Ringdén O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren HG; Malmberg KJ
    Blood; 2010 Apr; 115(13):2686-94. PubMed ID: 20097883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
    Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Weisdorf D; Cooley S; Devine S; Fehniger TA; DiPersio J; Anasetti C; Waller EK; Porter D; Farag S; Drobyski W; Defor T; Haagenson M; Curtsinger J; Miller J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):937-43. PubMed ID: 22155505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
    Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
    Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
    Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong AS; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
    Leukemia; 2007 Oct; 21(10):2145-52. PubMed ID: 17673900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
    Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
    Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
    Rizzieri DA; Crout C; Storms R; Golob J; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Lagoo AS; Morris A; Beaven A; Yang Y; Peterson B; Li Z; Chao NJ
    Cancer Invest; 2011 Jan; 29(1):56-61. PubMed ID: 21166499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.
    Dulphy N; Haas P; Busson M; Belhadj S; Peffault de Latour R; Robin M; Carmagnat M; Loiseau P; Tamouza R; Scieux C; Rabian C; Di Santo JP; Charron D; Janin A; Socié G; Toubert A
    J Immunol; 2008 Aug; 181(3):2227-37. PubMed ID: 18641363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
    Cooley S; Parham P; Miller JS
    Blood; 2018 Mar; 131(10):1053-1062. PubMed ID: 29358179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors.
    Kalwak K; Mosoń I; Cwian J; Gorczyńska E; Toporski J; Turkiewicz D; Latos-Grazyńska E; Chybicka A
    Transplant Proc; 2003 Jun; 35(4):1551-5. PubMed ID: 12826218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Tammik L; Omazic B; Levitsky V; Zou JZ; Hentschke P; Ringdén O
    Clin Exp Immunol; 2001 Jan; 123(1):162-9. PubMed ID: 11168014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
    Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
    Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.
    Shaffer BC; Hsu KC
    Semin Hematol; 2020 Oct; 57(4):167-174. PubMed ID: 33256909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the role for donor natural killer cells after nonmyeloablative conditioning?
    Baron F; Petersdorf EW; Gooley T; Sandmaier BM; Malkki M; Chauncey TR; Maloney DG; Storb R
    Biol Blood Marrow Transplant; 2009 May; 15(5):580-8. PubMed ID: 19361750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.